Atlas Molecular Pharma Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Atlas Molecular Pharma Limited - overview
Established
2015
Location
Derio, -, Spain
Primary Industry
Biotechnology
About
Based in Bizkaia, Spain, and founded in 2015, Atlas Molecular Pharma, a Spin-off of the CIC-Biogune research center, operates as a pharmaceutical research and development company that for the treatment of rare and ultra-rare metabolic diseases. In January 2026, Atlas Molecular Pharma raised EUR 5. 5 million in equity and grant funding led by Inveready Asset Management, with participation Center for Technological & Industrial Development, Kereon Partners, Gestion de Capital Riesgo del Pais Vasco, Endometrial DIDI, CRB Inverbio, and U. S.
Food and Drug Administration. The firm develops its proprietary technology called Chassys ™ which is an NMR-based technology that develops therapies to correct the phenotype for a range of rare diseases. The firm offers disease-specific pharmacological chaperones for diseases like congenital erythropoietic porphyria, prion diseases, and tyrosinemia type I. The company will use the January 2026 funding to advance the clinical development of ATL‑001 through a Phase I‑II trial.
Current Investors
Inveready Asset Management, Gestion de Capital Riesgo del Pais Vasco, Center for Technological & Industrial Development
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceuticals, Pharmaceutical Research & Development
Website
www.atlasmolecularpharma.com/
Verticals
Research (Non-Medical)
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.